IL297111A - Peptide labels and binding partners - Google Patents

Peptide labels and binding partners

Info

Publication number
IL297111A
IL297111A IL297111A IL29711122A IL297111A IL 297111 A IL297111 A IL 297111A IL 297111 A IL297111 A IL 297111A IL 29711122 A IL29711122 A IL 29711122A IL 297111 A IL297111 A IL 297111A
Authority
IL
Israel
Prior art keywords
seq
binding partner
peptide tag
homology
peptide
Prior art date
Application number
IL297111A
Other languages
English (en)
Hebrew (he)
Original Assignee
Adaptvac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptvac Aps filed Critical Adaptvac Aps
Publication of IL297111A publication Critical patent/IL297111A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
IL297111A 2020-05-07 2021-05-07 Peptide labels and binding partners IL297111A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20173377 2020-05-07
PCT/EP2021/062113 WO2021224451A1 (en) 2020-05-07 2021-05-07 Peptide tags and binding partners

Publications (1)

Publication Number Publication Date
IL297111A true IL297111A (en) 2022-12-01

Family

ID=70613720

Family Applications (1)

Application Number Title Priority Date Filing Date
IL297111A IL297111A (en) 2020-05-07 2021-05-07 Peptide labels and binding partners

Country Status (11)

Country Link
US (1) US20230321260A1 (enExample)
EP (1) EP4146675A1 (enExample)
JP (2) JP7843245B2 (enExample)
KR (1) KR20230006473A (enExample)
CN (1) CN115698045A (enExample)
AU (1) AU2021268757A1 (enExample)
BR (1) BR112022019632A2 (enExample)
CA (1) CA3177709A1 (enExample)
IL (1) IL297111A (enExample)
MX (1) MX2022013938A (enExample)
WO (1) WO2021224451A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526376B2 (en) 2015-01-15 2020-01-07 University Of Copenhagen Virus-like particle with efficient epitope display
WO2022229817A1 (en) * 2021-04-28 2022-11-03 Bavarian Nordic A/S Vaccines comprising virus-like particles displaying sars-cov-2 antigens and methods of use
US20240240203A1 (en) 2021-05-04 2024-07-18 SpyBiotech Limited Adenoviral vectors and vaccines thereof
EP4593874A2 (en) 2022-09-30 2025-08-06 Bavarian Nordic A/S Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
CN116165377A (zh) * 2023-04-21 2023-05-26 常州伯仪生物科技有限公司 一种通过竞争elisa法进行标签蛋白定量的方法
WO2025097030A1 (en) * 2023-11-02 2025-05-08 Oregon State University Virus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea
GB202317925D0 (en) 2023-11-23 2024-01-10 Spybiotech Ltd Vaccines
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
WO2026039325A2 (en) 2024-08-12 2026-02-19 Regeneron Pharmaceuticals, Inc. Modified mtm1 genes and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
SG10201801320UA (en) * 2014-11-03 2018-04-27 Merck Patent Gmbh Soluble intein fusion proteins and methods for purifying biomolecules
US10526376B2 (en) 2015-01-15 2020-01-07 University Of Copenhagen Virus-like particle with efficient epitope display
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
JP2019535321A (ja) * 2016-11-16 2019-12-12 オークランド ユニサービシーズ リミティド タンパク質ライゲーションの方法及びその使用
CN111073925B (zh) * 2018-10-19 2022-04-26 北京大学 一种基于无序蛋白偶联酶的高效多肽-多肽偶联系统和方法

Also Published As

Publication number Publication date
JP2026048917A (ja) 2026-03-17
JP2023525752A (ja) 2023-06-19
WO2021224451A9 (en) 2022-05-27
CN115698045A (zh) 2023-02-03
BR112022019632A2 (pt) 2023-10-03
WO2021224451A1 (en) 2021-11-11
MX2022013938A (es) 2022-11-30
AU2021268757A1 (en) 2022-12-08
US20230321260A1 (en) 2023-10-12
KR20230006473A (ko) 2023-01-10
JP7843245B2 (ja) 2026-04-09
EP4146675A1 (en) 2023-03-15
CA3177709A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
US20230321260A1 (en) Peptide tags and binding partners
CN113861278B (zh) 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用
US10247727B2 (en) Peptide tag system that spontaneously form an irreversible link to protein partners via isopeptide bonds
CN113621031B (zh) 一种利用自发异肽键进行蛋白共价自组装的肽链接头的组合
CN1561394A (zh) 人嗜中性粒细胞明胶酶相关脂卡林及有关蛋白的突变蛋白
CN116199733A (zh) 融合蛋白合成的方法和产品
CN111320684B (zh) 人源N-甲基-D-天冬氨酸受体的GluN1/GluN2A四聚体的表达及其应用
CN114315989A (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
JP2023551047A (ja) ウイルス様粒子及びそれらの製造方法
CN114560915A (zh) 一种改造的高滴度SARS-CoV-2假病毒
CN113121704B (zh) 基于纳米颗粒的冠状病毒疫苗
CN109852632A (zh) spoIIIJ蛋白作为芽孢杆菌表面展示系统中锚定蛋白的用途
CN113502294A (zh) 新型冠状病毒rbd蛋白的制备方法以及新型冠状病毒疫苗
CN113144187A (zh) 一种含EB病毒gHgLgp42蛋白的自组装纳米颗粒及其制备方法与应用
US20220324918A1 (en) SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF
CN114478717B (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
KR102014901B1 (ko) 단백질에 대한 나노운반체로서의 순도 및 안정성이 증진된 바이러스 유사 입자의 제조방법
WO2026037258A1 (zh) 具有改善的热稳定性的分选酶
HK40067420A (en) Recombinant trimeric rbd protein vaccine of novel coronavirus capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof
HK40067420B (en) Recombinant trimeric rbd protein vaccine of novel coronavirus capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof
CN122038361A (zh) 一种高亲和力的肉毒杆菌神经毒素a受体结合结构域突变体及其应用
HK40067421A (en) Recombinant trimeric rbd protein vaccine of novel coronavirus capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof
HK40067421B (en) Recombinant trimeric rbd protein vaccine of novel coronavirus capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof
HK40073048A (en) A recombinant protein-based covid-19 vaccine as well as its preparation method and application thereof
TW202313661A (zh) 嵌合型氣體囊泡及其蛋白質表現系統